Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension ...Middle East

Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action RARITAN, N.J., Nov. 7, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study,...

Hence then, the article about late breaking data from pivotal phase 3 precision study demonstrates significant and sustained effect of aprocitentan on lowering blood pressure for patients with difficult to control hypertension was published today ( Tuesday 08/11/2022 - 12:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension )

Also on site :

• US trade with Southeast Asia and Taiwan surging despite Trump tariffs
• Amazon Is Selling a 'Beautiful' $19 Cherry Blossom Tree Lamp That 'Looks Lovely at Night'
• Netflix Reboots Star Search: Who Won Big On Night 1? And Are You Vibing With The Judges? Grade The Premiere!